Pathology

The Rainwater Charitable Foundation Announces 2024 Rainwater Prize Winners, Dr. Virginia Man-Yee Lee and Dr. Cristian Lasagna-Reeves, for Ongoing Contributions to Scientific Understanding of Tau in the Brain

Retrieved on: 
Thursday, February 15, 2024

FORT WORTH, Texas, Feb. 15, 2024 /PRNewswire/ -- The Rainwater Charitable Foundation, one of the largest independent funders of neurodegenerative research that enables field-advancing programs, resources and breakthrough solutions for primary tauopathies, today announced Virginia Man-Yee Lee, Ph.D., University of Pennsylvania Perelman School of Medicine, will be awarded the 2024 Outstanding Innovation in Neurodegenerative Disease Research Prize of $400,000, and Cristian Lasagna-Reeves, Ph.D., M.S., Indiana University School of Medicine will be awarded the Rainwater Prize for Innovative Early-Career Scientist of $200,000. The prizes will be presented during the Tau2024 Global Conference on March 25-26, 2024, in Washington, D.C.

Key Points: 
  • The Rainwater Prize Program , now in its fifth year, aims to highlight and support scientific progress toward addressing critical gaps for neurodegenerative diseases associated with the accumulation of the tau protein in the brain.
  • Currently, Dr. Lasagna-Reeves' lab focuses on understanding the role of tau in Alzheimer's disease and related dementias.
  • Dr. Lasagna-Reeves winning this year's Early-Career Prize recognizes the scientific discoveries that could lead to a potential new therapeutic approach for tauopathies.
  • We're proud to support their research and provide resources that may contribute to potential future breakthroughs in our understanding of tau."

Enhance Your Sample Analysis with FRITSCH's New Mini Cutting Mill, Featured at Pittcon 2024

Retrieved on: 
Thursday, February 15, 2024

PITTSBORO, N.C., Feb. 15, 2024 /PRNewswire/ -- FRITSCH proudly presents its latest innovation, the PULVERISETTE 29 Mini Cutting Mill.

Key Points: 
  • PITTSBORO, N.C., Feb. 15, 2024 /PRNewswire/ -- FRITSCH proudly presents its latest innovation, the PULVERISETTE 29 Mini Cutting Mill.
  • The new PULVERISETTE 29 is the go-to solution for affordable, high-quality sample processing with homogeneous analytical fineness.
  • This product sets a benchmark in reproducible sample preparation, crucial for analyzing moisture, raw fiber, ash, minerals, and more.
  • Discover the PULVERISETTE 29 Mini Cutting Mill by FRITSCH - the ultimate tool for precise sample preparation.

Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

Retrieved on: 
Thursday, February 15, 2024

CAPE CANAVERAL, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced the publication of data from multiple non-human primate studies demonstrating that VXX-401 reproducibly lowers low-density lipoprotein cholesterol (LDL-C) in non-human primates. The results, which support the continued clinical development of VXX-401 as a candidate for the treatment of hypercholesterolemia and prevention of atherosclerotic cardiovascular disease, were published in the Journal of Lipid Research (Volume 65, Issue 2, 100497, February 2024).

Key Points: 
  • Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys.
  • The results, which support the continued clinical development of VXX-401 as a candidate for the treatment of hypercholesterolemia and prevention of atherosclerotic cardiovascular disease, were published in the Journal of Lipid Research (Volume 65, Issue 2, 100497, February 2024).
  • “Vaxxinity is committed to providing scalable, accessible, game-changing solution for worldwide heart health,” said Mei Mei Hu, CEO of Vaxxinity.
  • A cholesterol vaccine like VXX-401 may provide a cost-effective and widely deployable solution that could potentially benefit hundreds of millions of people at risk.

Renowned Urologist Endorses ProstatID as Game-Changer in Prostate Health Assessment

Retrieved on: 
Wednesday, February 14, 2024

It's remarkable efficiency in providing quick results has greatly facilitated my practice as a urologist.

Key Points: 
  • It's remarkable efficiency in providing quick results has greatly facilitated my practice as a urologist.
  • ProstatID transcends the limitations of conventional radiology reporting by offering a visual understanding of prostate conditions, thereby enhancing communication with patients and guiding diagnostic and treatment decisions with exceptional precision.
  • Upon reviewing cases of patients with multiple negative MRIs but persistent clinical symptoms suggestive of underlying cancer, ProstatID revealed previously undetected cancerous lesions.
  • Without a doubt, every urologist dealing with prostate conditions should incorporate ProstatID into their practice.

Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY

Retrieved on: 
Tuesday, February 13, 2024

Both pathology and products divisions have demonstrated substantial growth from 2023, with the pathology services division increasing revenue by 52%, and the products division increasing revenue by 115%.

Key Points: 
  • Both pathology and products divisions have demonstrated substantial growth from 2023, with the pathology services division increasing revenue by 52%, and the products division increasing revenue by 115%.
  • With a $1.5M cash balance ending 2023, the company is positioned to achieve its goal of reaching profitability.
  • “Continued growth in both the pathology services and the products divisions is fueling our path towards profitability.
  • Reaching this goal will enable us to scale the business and capture significant market share, resulting in increased shareholder value,” said Ilan Danieli, CEO.

Roche enters into collaboration agreement with PathAI to expand digital pathology capabilities for companion diagnostics

Retrieved on: 
Tuesday, February 13, 2024

PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business.

Key Points: 
  • PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business.
  • The image analysis algorithms will be deployed on Roche's navify Digital Pathology platform, allowing seamless integration into pathology laboratories worldwide.
  • The collaboration between RTD and PathAI helps advance precision medicine by bringing together AI-interpretation and companion diagnostics, increasing patient access to targeted treatments.
  • Under the terms of this agreement, PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop AI-enabled digital pathology algorithms in the companion diagnostics space.

David Bruning Named Chief Executive Officer of StageBio

Retrieved on: 
Monday, February 12, 2024

JACKSON, Va., Feb. 12, 2024 /PRNewswire/ -- StageBio, a leading provider of GLP-compliant histology, pathology, image analysis and archiving services for both preclinical and clinical research, is pleased to announce the appointment of David Bruning as Chief Executive Officer.

Key Points: 
  • JACKSON, Va., Feb. 12, 2024 /PRNewswire/ -- StageBio, a leading provider of GLP-compliant histology, pathology, image analysis and archiving services for both preclinical and clinical research, is pleased to announce the appointment of David Bruning as Chief Executive Officer.
  • Having served on the StageBio Board of Directors for the past five years in addition to previously being a longstanding customer of StageBio, Mr. Bruning possesses a deep understanding of the company, its strategic priorities and the evolving needs of its customers.
  • On his appointment as CEO, Mr. Bruning comments, "I'm grateful for the opportunity to lead StageBio in its next phase of growth.
  • David's understanding of the business and its customers, coupled with his industry expertise, positions him for success in driving continuous growth for StageBio in 2024 and beyond."

Accelus Strengthens Leadership with New Board Appointments

Retrieved on: 
Monday, February 12, 2024

This strategic enhancement to the board is aligned with Accelus’s mission to deliver innovative spinal solutions that elevate the surgical experience and improve patient outcomes.

Key Points: 
  • This strategic enhancement to the board is aligned with Accelus’s mission to deliver innovative spinal solutions that elevate the surgical experience and improve patient outcomes.
  • His journey with Accelus includes key roles as President and Chief Commercial Officer, showcasing his leadership and strategic vision.
  • Bernie Haffey, the founder of Haffey & Co., brings to the board a proven track record in executive management and leadership.
  • “I am delighted by the addition of Kevin McGann and Bernie Haffey to the Accelus Board of Directors," said Alex Lukianov, Chairman of the Board for Accelus.

Proscia Receives FDA 510(k) Clearance For Concentriq AP-Dx

Retrieved on: 
Monday, February 12, 2024

PHILADELPHIA, Feb. 12, 2024 /PRNewswire-PRWeb/ -- Proscia®, a leading provider of digital and computational pathology solutions, has received 510(k) clearance from the United States (U.S.) Food and Drug Administration (FDA) for its Concentriq® AP-Dx*. The digital pathology solution was cleared for the purpose of primary diagnosis.

Key Points: 
  • PHILADELPHIA, Feb. 12, 2024 /PRNewswire-PRWeb/ -- Proscia® , a leading provider of digital and computational pathology solutions, has received 510(k) clearance from the United States (U.S.) Food and Drug Administration (FDA) for its Concentriq® AP-Dx*.
  • Concentriq AP-Dx was designed to be used in clinical settings of all sizes, from individual reference laboratories to the largest hospital systems.
  • In support of its 510(k) clearance, Proscia conducted a multi-site clinical study at PathGroup, South Bend Medical Foundation, and Spectrum Healthcare Partners.
  • In addition to its 510(k) clearance, Proscia was the first company to achieve CE-IVDR certification to advance primary diagnosis in the European Union.

Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Retrieved on: 
Thursday, February 8, 2024

ATH-1105 is a next-generation, orally administered small molecule drug candidate designed to enhance the neurotrophic hepatocyte growth factor (HGF) system.

Key Points: 
  • ATH-1105 is a next-generation, orally administered small molecule drug candidate designed to enhance the neurotrophic hepatocyte growth factor (HGF) system.
  • “These data demonstrate that ATH-1105 treatment results in significant, consistent beneficial effects both in cell culture and in vivo models of ALS.
  • “There is an urgent need for new ALS treatment options, particularly those aimed at slowing or stopping neurodegeneration,” said Mark Litton, Ph.D., President and Chief Executive Officer of Athira.
  • These findings further support our plans to progress ATH-1105 into first-in-human studies in the first half of 2024.”